Precigen, Inc. (PGEN): Price and Financial Metrics


Precigen, Inc. (PGEN): $7.48

0.21 (+2.89%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PGEN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 493

in industry

PGEN Stock Summary

  • With a price/sales ratio of 14.49, Precigen Inc has a higher such ratio than 86.7% of stocks in our set.
  • PGEN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 79.06% of US stocks.
  • With a year-over-year growth in debt of -26.48%, Precigen Inc's debt growth rate surpasses only 13.79% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Precigen Inc, a group of peers worth examining would be TUFN, LC, BGMD, STXS, and WK.
  • PGEN's SEC filings can be seen here. And to visit Precigen Inc's official web site, go to www.precigen.com.

PGEN Stock Price Chart Interactive Chart >

Price chart for PGEN

PGEN Price/Volume Stats

Current price $7.48 52-week high $11.10
Prev. close $7.27 52-week low $2.14
Day low $7.23 Volume 325,087
Day high $7.64 Avg. volume 1,671,841
50-day MA $8.00 Dividend yield N/A
200-day MA $6.55 Market Cap 1.54B

Precigen, Inc. (PGEN) Company Bio


Precigen, Inc. (formerly Intrexon Corporation) provides synthetic biology services. The Company designs and produces modular DNA control systems and applications for human therapeutics, protein production, industrial products, agricultural biotechnology, and animal sciences. The company was founded in 1998 and is based in Germantown, Maryland.


PGEN Latest News Stream


Event/Time News Detail
Loading, please wait...

PGEN Latest Social Stream


Loading social stream, please wait...

View Full PGEN Social Stream

Latest PGEN News From Around the Web

Below are the latest news stories about Precigen Inc that investors may wish to consider to help them evaluate PGEN as an investment opportunity.

Precigen Announces Departure of Chief Financial Officer

Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that by mutual agreement Rick Sterling is stepping down from his position as Chief Financial Officer effective April 2, 2021. Precigen has commenced an executive search for a successor with the qualifications to contribute to Precigen's accelerating growth from a clinical stage company to a commercial organization.

Yahoo | March 30, 2021

How Much Of Precigen, Inc. (NASDAQ:PGEN) Do Insiders Own?

Every investor in Precigen, Inc. ( NASDAQ:PGEN ) should be aware of the most powerful shareholder groups. Institutions...

Yahoo | March 25, 2021

Precigen Receives FDA Orphan Drug Designation for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)

Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy for recurrent respiratory papillomatosis (RRP). In January 2021, Precigen announced the clearance of the IND to Initiate a Phase I study of PRGN-2012 AdenoVerse™ immunotherapy in adult patients with RRP (clinical trial identifier: NCT04724980). PRGN-2012 is under development through a Cooperative Research and Development Agreement (CRADA) with the Center for Cancer Research (CCR) at the National Cancer Institute (NCI), which is part of the Natio...

Yahoo | March 18, 2021

Precigen Reports Fourth Quarter and Full Year 2020 Financial Results

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced fourth quarter and full year 2020 financial results.

Yahoo | March 1, 2021

Precigen, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 1, 2021 / Precigen, Inc. (NASDAQ:PGEN) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 1, 2021 at 4:30 PM Eastern Time.

Yahoo | March 1, 2021

Read More 'PGEN' Stories Here

PGEN Price Returns

1-mo -15.86%
3-mo -6.62%
6-mo 54.87%
1-year 175.00%
3-year -60.34%
5-year -80.30%
YTD -26.67%
2020 86.13%
2019 -16.21%
2018 -43.23%
2017 -52.59%
2016 -19.40%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.1927 seconds.